Last reviewed · How we verify
pregabalin capsules
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters. Used for Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury), Partial-onset seizures (adjunctive therapy), Generalized anxiety disorder.
At a glance
| Generic name | pregabalin capsules |
|---|---|
| Also known as | LYRICA (pregabalin) |
| Sponsor | AstraZeneca |
| Drug class | Gabapentinoid; anticonvulsant; anxiolytic |
| Target | Alpha-2-delta-1 subunit of voltage-gated calcium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology; Pain Management; Psychiatry |
| Phase | FDA-approved |
Mechanism of action
By binding to the alpha-2-delta-1 subunit on presynaptic calcium channels, pregabalin decreases calcium influx and subsequently reduces the release of glutamate, noradrenaline, and substance P. This leads to decreased neuronal excitability and pain signal transmission. The drug is structurally related to GABA but does not directly bind GABA receptors; instead, its analgesic and anxiolytic effects result from modulation of calcium channel function.
Approved indications
- Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury)
- Partial-onset seizures (adjunctive therapy)
- Generalized anxiety disorder
- Fibromyalgia
Common side effects
- Dizziness
- Somnolence
- Dry mouth
- Edema (peripheral)
- Weight gain
- Blurred vision
- Ataxia
Key clinical trials
- Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy (PHASE2)
- A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Pain (PHASE1)
- Adding Amantadine or Duloxetine to Pregabalin on Occurrence of Post Mastectomy Pain Syndrome (NA)
- Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal (PHASE2)
- Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy (PHASE3)
- Oral Melatonin Versus Oral Pregabalin on Postoperative Pain and Anxiety Following Spine Surgery (NA)
- Combination of Duloxetine and Pregabalin to Improve Postoperative Pain (PHASE1)
- The Efficacy and Safety of Pregabalin Combined With Venlafaxine in Patients With Fibromyalgia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pregabalin capsules CI brief — competitive landscape report
- pregabalin capsules updates RSS · CI watch RSS
- AstraZeneca portfolio CI